Resistance Exercise in Patients With Ocular Melanoma
NCT06970236 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2025-05-28
Summary
Choroidal melanoma (CM) is one of the most common intraocular cancers worldwide. During treatment with episcleral brachytherapy, patients require a week of hospitalization in isolation. The primary aim of this study will be to investigate the effects of resistance training during hospitalization on health-related blood biomarkers in CM patients. Our secondary aim will be to assess changes in physical function tests, quality of life and anxiety and depression. Candidates for this study will be patients undergoing CM treatment at the "Hospital Universitari i Politècnic La Fe" of Valencia.
Conditions
- Ocular Melanoma
Interventions
- OTHER
-
Exercise
Daily session during hospitalization. To carry out the training session, elastic bands (TheraBand CLX Consecutive Loops; TheraBand, Akron, OH) with resistance graded from very low to very high (i.e, yellow, red, green, blue, black, silver and gold) will be used. On each day, each exercise will start with 3 sets of two repetitions as a warm-up and to calculate the appropriate intensity. The intensity will be that at which the patient reports a perceived exertion of 5-6 of 10 at the Borg CR10 scale after two repetitions. For each exercise, one set will be completed until task failure is achieved.If in any of the exercises the patient perceives this intensity only with the weight of his own limb or body weight, the exercise will be performed without elastic bands.
Sponsors & Collaborators
-
University of Valencia
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-02-01
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- Spain
Study Locations
More Related Trials
-
3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With Melanoma
NCT03825913 ·Status: TERMINATED ·Phase: NA
-
Melphalan Chemoreduction for Ocular Melanoma
NCT05893654 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma
NCT03472027 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
NCT06627595 ·Status: RECRUITING
-
Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
NCT01893099 ·Status: COMPLETED ·Phase: PHASE1
-
Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
NCT06073548 ·Status: NOT_YET_RECRUITING
-
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
NCT00050102 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
NCT01376713 ·Status: COMPLETED ·Phase: PHASE2
-
Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma
NCT00406900 ·Status: UNKNOWN
-
Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice
NCT05402059 ·Status: UNKNOWN
-
Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors
NCT03946007 ·Status: COMPLETED
-
Retrospective Register for Uveal Melanoma
NCT05733728 ·Status: RECRUITING
-
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
NCT03417739 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma
NCT01614301 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
NCT00729950 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma
NCT03913923 ·Status: UNKNOWN ·Phase: PHASE2
-
Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma
NCT02673970 ·Status: RECRUITING
-
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
NCT01143402 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
NCT04370704 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
NCT05180942 ·Status: RECRUITING
-
Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
NCT03964298 ·Status: COMPLETED
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
NCT05907954 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Radiation and Combination Immunotherapy for Melanoma
NCT03850691 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190 ·Status: RECRUITING ·Phase: PHASE3
-
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
NCT02107755 ·Status: COMPLETED ·Phase: PHASE2